AI Biotech Peptris Secures $7.7 Million to Revolutionize Drug Discovery
February 26, 2026, 9:37 pm
Peptris, a Bengaluru-based AI drug discovery company, secured $7.7 million (Rs 70 crore) in Series A funding. This investment propels the expansion of its AI-led platform, accelerating novel molecule generation and advancing programs toward clinical trials. The company tackles drug development's high costs and failures, focusing on rare diseases, oncology, inflammation, and women's health. Peptris aims to identify new chemical entities, repurpose existing drugs, and rescue promising compounds. Strategic growth includes expanding its scientific teams and building global partnerships to deliver impactful healthcare solutions, making drug discovery faster, more efficient, and patient-centric. This funding marks a significant stride in AI-driven biotech innovation.
Bengaluru’s Peptris, a pioneering AI drug discovery firm, has closed a Series A funding round. The company secured Rs 70 crore, equivalent to $7.7 million. This substantial capital infusion will propel Peptris’s advanced artificial intelligence platform forward. Investment was co-led by IAN Alpha Fund and Speciale Invest. Other key participants included Tenacity Ventures and BYT Ventures, among others. This funding signals strong investor confidence in AI’s transformative power within biotechnology.
Drug discovery has long faced immense challenges. It is a slow, costly, and failure-prone endeavor. Many promising compounds never reach patients. Significant medical needs remain unmet globally. The pre-clinical phase is particularly risky. Scientific uncertainty often derails programs before clinical trials begin. Peptris directly addresses these critical inefficiencies. Their platform offers a radical departure from traditional methods.
Peptris employs sophisticated AI models. These models generate novel molecules. They also predict crucial drug development parameters early. This capability is paramount. It enables quicker, more informed decision-making. Such foresight drastically reduces the likelihood of late-stage failures. This approach saves valuable time and resources. It accelerates the journey from lab to clinic.
The company’s AI engine delivers multiple strategic advantages. It identifies Novel Chemical Entities (NCEs). These are entirely new compounds with therapeutic potential. The platform also uncovers opportunities for drug repurposing. Existing drugs can find new applications against different diseases. Furthermore, it facilitates drug rescue. This involves salvaging promising compounds previously shelved due to unforeseen challenges. Peptris is actively advancing several programs closer to clinical development.
Funding will fuel a significant expansion phase. Peptris plans to scale its teams across multiple disciplines. Biology, chemistry, data science, and artificial intelligence departments will grow. This multidisciplinary approach strengthens their innovation engine. A broader talent pool will accelerate research and development initiatives. It ensures a robust pipeline of new therapeutic candidates.
Over the next 24 months, Peptris will expand its pipeline aggressively. Numerous new NCE programs are slated for initiation. Multiple drug repurposing and rescue programs are also in the works. These efforts aim to bring diverse solutions to pressing health problems. The company is committed to pushing existing programs toward clinical readiness. This means meticulous preclinical testing and regulatory preparation.
Peptris operates on a B2B engagement model. It partners closely with pharmaceutical and biotech companies. Select FMCG partners also collaborate. This model involves licensing assets and co-developing programs. Strong alliances are crucial for accelerating drug development. They provide access to extensive resources and market reach. These collaborations ensure Peptris's innovations translate into tangible patient benefits.
The company focuses on specific therapeutic areas. These include rare diseases, inflammation, oncology, and women’s health. These fields represent areas of high unmet medical need. Rare diseases often lack effective treatments entirely. Oncology demands continuous innovation against evolving cancers. Inflammation plays a role in numerous chronic conditions. Women’s health presents unique challenges requiring dedicated solutions. Peptris aims for a lasting impact on patients, caregivers, and healthcare systems worldwide.
The founders bring extensive expertise to the venture. Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan co-founded Peptris in 2019. Their collective backgrounds span AI drug discovery and computational science. This deep domain knowledge underpins the company’s technological prowess. Their vision is to harness AI for significant healthcare challenges. The goal is to enhance quality of life, not merely extend lifespan.
The global pharmaceutical industry increasingly looks to AI. Artificial intelligence promises to streamline complex processes. It improves efficiency and accuracy. Peptris stands at the forefront of this revolution. Its platform offers a blueprint for future drug discovery. By predicting outcomes early, Peptris mitigates risks. It maximizes the potential for success in a challenging industry.
Peptris also intends to build business development capabilities. Efforts will focus on the US and European markets. This expansion strategy aims to deepen partnerships with global pharmaceutical and biotech companies. A wider international presence will accelerate drug deployment. It will broaden access to innovative therapies for patients worldwide. This strategic outreach is critical for global impact.
Ultimately, Peptris seeks to translate its work into hope. Patients with limited or unaffordable treatment options stand to benefit most. Caregivers facing immense burdens could find relief. The company envisions a more accessible future for all. This mission drives its technological advancements and strategic growth. The Series A funding provides vital momentum for this ambitious endeavor. It underscores AI's growing importance in shaping the future of medicine.
AI Breakthroughs Reshape Drug Discovery Landscape
Bengaluru’s Peptris, a pioneering AI drug discovery firm, has closed a Series A funding round. The company secured Rs 70 crore, equivalent to $7.7 million. This substantial capital infusion will propel Peptris’s advanced artificial intelligence platform forward. Investment was co-led by IAN Alpha Fund and Speciale Invest. Other key participants included Tenacity Ventures and BYT Ventures, among others. This funding signals strong investor confidence in AI’s transformative power within biotechnology.
Drug discovery has long faced immense challenges. It is a slow, costly, and failure-prone endeavor. Many promising compounds never reach patients. Significant medical needs remain unmet globally. The pre-clinical phase is particularly risky. Scientific uncertainty often derails programs before clinical trials begin. Peptris directly addresses these critical inefficiencies. Their platform offers a radical departure from traditional methods.
Peptris employs sophisticated AI models. These models generate novel molecules. They also predict crucial drug development parameters early. This capability is paramount. It enables quicker, more informed decision-making. Such foresight drastically reduces the likelihood of late-stage failures. This approach saves valuable time and resources. It accelerates the journey from lab to clinic.
The company’s AI engine delivers multiple strategic advantages. It identifies Novel Chemical Entities (NCEs). These are entirely new compounds with therapeutic potential. The platform also uncovers opportunities for drug repurposing. Existing drugs can find new applications against different diseases. Furthermore, it facilitates drug rescue. This involves salvaging promising compounds previously shelved due to unforeseen challenges. Peptris is actively advancing several programs closer to clinical development.
Funding will fuel a significant expansion phase. Peptris plans to scale its teams across multiple disciplines. Biology, chemistry, data science, and artificial intelligence departments will grow. This multidisciplinary approach strengthens their innovation engine. A broader talent pool will accelerate research and development initiatives. It ensures a robust pipeline of new therapeutic candidates.
Over the next 24 months, Peptris will expand its pipeline aggressively. Numerous new NCE programs are slated for initiation. Multiple drug repurposing and rescue programs are also in the works. These efforts aim to bring diverse solutions to pressing health problems. The company is committed to pushing existing programs toward clinical readiness. This means meticulous preclinical testing and regulatory preparation.
Peptris operates on a B2B engagement model. It partners closely with pharmaceutical and biotech companies. Select FMCG partners also collaborate. This model involves licensing assets and co-developing programs. Strong alliances are crucial for accelerating drug development. They provide access to extensive resources and market reach. These collaborations ensure Peptris's innovations translate into tangible patient benefits.
The company focuses on specific therapeutic areas. These include rare diseases, inflammation, oncology, and women’s health. These fields represent areas of high unmet medical need. Rare diseases often lack effective treatments entirely. Oncology demands continuous innovation against evolving cancers. Inflammation plays a role in numerous chronic conditions. Women’s health presents unique challenges requiring dedicated solutions. Peptris aims for a lasting impact on patients, caregivers, and healthcare systems worldwide.
The founders bring extensive expertise to the venture. Narayanan Venkatasubramanian, Shridhar Narayanan, Anand Budni, and Amit Mahajan co-founded Peptris in 2019. Their collective backgrounds span AI drug discovery and computational science. This deep domain knowledge underpins the company’s technological prowess. Their vision is to harness AI for significant healthcare challenges. The goal is to enhance quality of life, not merely extend lifespan.
The global pharmaceutical industry increasingly looks to AI. Artificial intelligence promises to streamline complex processes. It improves efficiency and accuracy. Peptris stands at the forefront of this revolution. Its platform offers a blueprint for future drug discovery. By predicting outcomes early, Peptris mitigates risks. It maximizes the potential for success in a challenging industry.
Peptris also intends to build business development capabilities. Efforts will focus on the US and European markets. This expansion strategy aims to deepen partnerships with global pharmaceutical and biotech companies. A wider international presence will accelerate drug deployment. It will broaden access to innovative therapies for patients worldwide. This strategic outreach is critical for global impact.
Ultimately, Peptris seeks to translate its work into hope. Patients with limited or unaffordable treatment options stand to benefit most. Caregivers facing immense burdens could find relief. The company envisions a more accessible future for all. This mission drives its technological advancements and strategic growth. The Series A funding provides vital momentum for this ambitious endeavor. It underscores AI's growing importance in shaping the future of medicine.